U.S. License Holder:
Novartis Pharms. Corp.
Date of License:
January-21-2015 [October-06-2023]
Last Update:
Nov-30-2023
FDA-Approved Indications
COSENTYX (secukinumab) is a human interleukin-17A antagonist indicated for the treatment of:
Moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy;
Active psoriatic arthritis (PsA) in patients 2 years of age and older;
Adults with active ankylosing spondylitis (AS);
Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation;
Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older;
Adults with moderate to severe hidradenitis suppurativa (HS).